FDA Rolls Out More New Indications for Existing Agents

September 25, 2019 by Kathleen Wiley RN, MSN, AOCNS®

Pembrolizumab, lenalidomide, and avelumab all received new treatment indications in spring 2019. Here’s what you need to know about dosing, adverse events, and other nursing considerations for these and other drugs that the U.S. Food and Drug Administration (FDA) approved from April–June 2019.

Breast Cancer

Head and Neck Cancer

Hematologic Cancer

Lung Cancer

Renal Cell Carcinoma

With the influx of oral treatments used as single-agent therapies as well as part of multidrug regimens, refer to ONS’s variety of oral therapy resources, including patient education sheets (http://oralchemoedsheets.com/) and an oral adherence toolkit (https://www.ons.org/toolkits/oral-adherence-toolkit)

Copyright © 2019 by the Oncology Nursing Society. User has permission to print one copy for personal or unit-based educational use. Contact pubpermissions@ons.org for quantity reprints.